USFDA issues 9 observations for Canada contract manufacturing facility: Jubilant Pharmova
Written By : Ruchika Sharma
Published On 2025-11-05 09:15 GMT | Update On 2025-11-05 09:15 GMT
Advertisement
Noida: Jubilant Pharmova Limited has announced that the United States Food and Drug Administration (USFDA) has concluded an audit of Jubilant HollisterStier General Partnership (“JHSGP”)’s contract manufacturing facility located in Montreal, Canada, with 9 observations.
"JHSGP will submit an action plan on the observations," the company stated in a BSE filing.
JHSGP is jointly owned by subsidiaries of Jubilant Pharma Limited, a wholly owned subsidiary of the Company.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.